Clozapine: reduction of the initial dopamine turnover increase by repeated treatment.
The levels of homovarillic acid and 3,4-dihydroxyphenylacetic acid in rat c. striatum after acute and 10 day administration of clozapine (30 and 100 mg/kg p.o.), thioridazine (100 mg/kg p.o.), haloperidol (1 mg/kg p.o.), and chlorpromazine (30 mg/kg p.o.), were estimated. With clozapine and haloperidol, the mesolimbic area was also investigated. With all these neuroleptics, the levels of both dopamine metabolites were reduced after a 10 day treatment as compared to acute administration, sometimes almost to control values. With clozapine, however, such a reduction occurred only with the higher dose of 100 mg/kg p.o., acting for a period longer than 24 h. This tolerance phenomenon was also observed with clozapine and haloperidol in the mesolimbic area. We conclude that clozapine is not qualitatively different from classical neuroleptics with respect to development of biochemical tolerance.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D002746:Chlorpromazine / Q000494:pharmacology; D003024:Clozapine / Q000494:pharmacology*; D003342:Corpus Striatum / Q000378:metabolism; D003984:Dibenzazepines / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism*; D004361:Drug Tolerance; D005260:Female; D006719:Homovanillic Acid / Q000378:metabolism; D008032:Limbic System / Q000378:metabolism; D051381:Rats; D013881:Thioridazine / Q000494:pharmacology; D013997:Time Factors
D003984:Dibenzazepines; D015102:3,4-Dihydroxyphenylacetic Acid; D003024:Clozapine; D013881:Thioridazine; D002746:Chlorpromazine; D004298:Dopamine; D006719:Homovanillic Acid